Heron Therapeutics (HRTX) Return on Equity (2011 - 2026)

Heron Therapeutics has reported Return on Equity for 16 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity fell 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (down 1.0% YoY), and the FY2025 full-year result was 0.01%, up 1.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.01%, down from 0.0% in the prior quarter.
• The five-year high for Return on Equity was 0.05% in Q2 2023, with the low at 5.82% in Q3 2022.
• Historically, Return on Equity has averaged 0.54% across 5 years, with a median of 0.0% in 2025.
• Annual changes were most pronounced in 2022 — Return on Equity tumbled 581 bps — and 2023, when it surged 586 bps.
• Heron Therapeutics' Return on Equity stood at 0.1% in 2022, then surged by 137 bps to 0.04% in 2023, then tumbled by 91 bps to 0.0% in 2024, then plunged by 156 bps to 0.0% in 2025, then tumbled by 413 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.